Fischer Medical Ventures Holds 33rd AGM via Video Conference on Sep 29, 2026
Fischer Medical Ventures Limited held its 33rd AGM on September 29, 2026, via video conference. Key management, including Chairman Mr. Ravindran Govindan and CFO Mr. Vivek Balasubramanian, addressed shareholder queries on international operations, growth, and financials. E-voting was conducted with NSDL facilitating the process.
The announcement details the proceedings of a routine Annual General Meeting, which is a standard corporate compliance event. It does not involve any new strategic decisions, financial outcomes, or operational changes that would significantly impact the company's business or stock performance.
The announcement is a summary of proceedings of the Annual General Meeting, which is a routine corporate event. It does not contain any new financial results or significant strategic announcements that would positively or negatively impact the company's outlook.
Fischer Medical Ventures Limited conducted its 33rd Annual General Meeting (AGM) on September 29, 2026, commencing at 11:00 AM IST, entirely through Video Conferencing.
The meeting was facilitated using services from National Securities Depositories Limited (NSDL) for video conferencing and e-voting. Present at the AGM were the Chairman & Managing Director, Mr. Ravindran Govindan, along with other Directors and Senior Managerial Personnel, including Ms. Svetlana Rao (Whole-Time Director), Mr. Khairy Jamaluddin Abu Bakar (Independent Director), and Mr. Vivek Balasubramanian (Chief Financial Officer). Representatives from the Statutory Auditors and Secretarial Auditors were also in attendance.
Sixty-one members joined the virtual AGM. The Company Secretary, Mr. Balaji Gandla, welcomed shareholders and introduced the board. Key procedural aspects were highlighted, including the use of video conferencing, e-voting mechanisms, and the availability of statutory registers on the company's website. A significant representation was received from one corporate member holding 50.78% of the equity share capital. The Annual Reports were distributed via email, and shareholders as of September 22, 2026, were eligible to vote. Mr. Nuren Lodaya, Practising Company Secretary, was appointed as the scrutinizer for the e-voting process. The Auditors' and Secretarial Auditors' reports were presented without qualifications.
Mr. Ravindran Govindan chaired the meeting and provided an outlook on the Company's performance. Resolutions were voted on through remote e-voting prior to the meeting, with a 30-minute window for e-voting after the AGM for those who had not voted remotely. Shareholders' questions, received via email and registered in advance, were addressed. Mr. Srikanth Jhawar and Ms. Hetvi Aatish Bhachech raised queries concerning international operations, growth, financial performance, R&D, capital allocation, and working capital management. Responses were provided by Mr. Shankar Varadharajan (COO), Ms. Svetlana Rao (Whole-Time Director), and Mr. Vivek Balasubramanian (CFO). The meeting concluded at 11:59 AM.
What to do with a filing like this
Fischer Medical Ventures Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fischer Medical Ventures Limited. Read the original for the full detail.